Skip to Content
  • Determination of the R-enantiomer of valsartan in pharmaceutical formulation by capillary electrophoresis.

Determination of the R-enantiomer of valsartan in pharmaceutical formulation by capillary electrophoresis.

Archives of pharmacal research (2014-07-24)
Kyung Ran Lee, NgocVan Thi Nguyen, Yong Jae Lee, Seungho Choi, Jong Seong Kang, Woongchon Mar, Kyeong Ho Kim
ABSTRACT

Capillary zone electrophoresis was successfully applied to the enantiomeric purity determination of valsartan using acetyl-β-cyclodextrin (A-β-CD) as a chiral selector. Separations were carried out in a 50 µm, 64/56 cm fused-silica capillary. The optimized conditions included 25 mM phosphate buffer, pH 8.0, containing 10 mM A-β-CD as background electrolyte, an applied voltage of +30 kV and a temperature of 30 °C. Ibuprofen was used as an internal standard. The assay was validated for the R-enantiomer of valsartan in the range of 0.05-3.0%. The limit of detection was 0.01%, the limit of quantitation was 0.05%, relative to a concentration of valsartan of 1 mg/ml. Intra-day precision varied between 2.57 and 5.60%. Relative standard deviations of inter-day precision ranged between 4.46 and 6.76% for peak area ratio. The percentage recovery of the R-enantiomer of valsartan ranged between 97.0 and 99.6% in valsartan product. The assay was applied to the determination of the chiral purity of valsartan tablets and R-enantiomer of valsartan was found as an impurity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Valsartan, ≥98% (HPLC)